Idalopirdine

Idalopirdine

Clinical data
Other names	Lu-AE-58054
ATC code	None
Identifiers
IUPAC name 2-(6-Fluoro-1H-indol-3-yl)-N-(3-(2,2,3,3-tetrafluoropropoxy)benzyl)ethanamine
CAS Number	467459-31-0 N
PubChem CID	21071390
ChemSpider	19878969 N
UNII	59WCJ0YNWM
KEGG	D10710 Y
ChEMBL	ChEMBL3286580
ECHA InfoCard	100.245.270
Chemical and physical data
Formula	C20H19F5N2O
Molar mass	398.377 g·mol−1
3D model (JSmol)	Interactive image
SMILES FC(F)C(F)(F)COc1cccc(c1)CNCCc3c[nH]c2cc(F)ccc23
InChI InChI=1S/C20H19F5N2O/c21-15-4-5-17-14(11-27-18(17)9-15)6-7-26-10-13-2-1-3-16(8-13)28-12-20(24,25)19(22)23/h1-5,8-9,11,19,26-27H,6-7,10,12H2 N Key:YBAWYTYNMZWMMJ-UHFFFAOYSA-N N
NY (what is this?)  (verify)

Idalopirdine (INN) (code names Lu AE58054,) is a potent and selective 5-HT₆ receptor antagonist under development by Lundbeck as an augmentation therapy for the treatment of cognitive deficits associated with Alzheimer's disease and schizophrenia. As of October 2013 it is in phase III clinical trials.

A phase III trial of two different daily doses of Lu AE58054 on top of 10 mg of donepezil for mild-to-moderate Alzheimer's failed to meet its primary endpoint with either dose. Two further phase III trials failed too, the company confirmed in early 2017.

See also

• Cerlapirdine
• Latrepirdine

External links

• Lundbeck expands its pipeline - initiating phase II clinical trials with a new compound for the treatment of schizophrenia Archived 2011-07-09 at the Wayback Machine
• Lundbeck initiates clinical phase II trials with Lu AE58054 as augmentation treatment in Alzheimer's disease Archived 2010-02-04 at the Wayback Machine